Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - Priority Announcement: Neuromuscular Research

Université Laval

$197,418.00

Glia-neuron crosstalk in early amyotrophic lateral sclerosis pathogenesis

FY 2010-11

Summary
Amyotrophic Lateral Sclerosis (ALS) is a late onset neurodegenerative disorder characterized by selective loss of motor neurons, muscle weakness and eventual paralysis, leading to a death within the 2-5 years following diagnosis. Presently, there is no efficient therapy to treat or to slow down the disease progression. Moreover, despite intensive research efforts the pathological events precipitating disease onset and the exact patterns of early disease spreading are not yet fully understood. Because understanding of early pathological events in ALS is crucial for creation of more efficient therapeutic strategies, we recently developed series novel ALS mouse models in which we can visualize from the live animals early pathological events and image disease progression and therapeutic efficacy. Using novel disease models and live imaging approaches, our main goal is to better understand early pathological events in ALS and use this knowledge to create novel and more efficient therapeutic strategies.
Program
Operating Grant - Priority Announcement: Neuromuscular Research
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
230646
Name
Kriz Jasna
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Amyotrophic Lateral Sclerosis Society of Canada
Instname2
Aging
Theme2
Biomedical
Prcname2
Systems & Circuits Neurosciences - A
Projecttitle
Glia-neuron crosstalk in early amyotrophic lateral sclerosis pathogenesis
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$197,418
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Neuromuscular Research
Keyworddelim
Amyotrophic Lateral Sclerosis; Behavioral Analysis; Bioluminescence; Immunocytochemistry; Immunotherapy; In Situ Hybridization; In Vivo Pharmacology; Live Small Animal Molecular Imaging; Microglia And Astrocyte Activation; Neurodegeneration; Protein Analysis; Sod1 Mutant Mice; Tdp43 Mutant; Transgenic Mice For In Vivo Imaging Of Neuroinflamamtion
Abstract
Amyotrophic Lateral Sclerosis (ALS) is a late onset neurodegenerative disorder characterized by selective loss of motor neurons, muscle weakness and eventual paralysis, leading to a death within the 2-5 years following diagnosis. Presently, there is no efficient therapy to treat or to slow down the disease progression. Moreover, despite intensive research efforts the pathological events precipitating disease onset and the exact patterns of early disease spreading are not yet fully understood. Because understanding of early pathological events in ALS is crucial for creation of more efficient therapeutic strategies, we recently developed series novel ALS mouse models in which we can visualize from the live animals early pathological events and image disease progression and therapeutic efficacy. Using novel disease models and live imaging approaches, our main goal is to better understand early pathological events in ALS and use this knowledge to create novel and more efficient therapeutic strategies.
Competitiondate
201103
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kriz, Jasna
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $65,834~ $0~Inst of Neurosc Mental Hlth &A~ $65,834~ $0~Institute of Genetics~ $65,750~ $0~
Université Laval - $197,418 Grant (2010-11) | Canada Spends